CJ 033466

Key Product Details

Product Description

CJ 033466 is a potent and selective 5-HT₄ partial agonist (EC₅₀= 0.927 nM). Displays > 1000-fold selectivity for 5-HT₄ over other 5-HT and D₂ receptors. Exhibits gastroprokinetic effects in vivo following oral administration. Weakly blocks hERG (IC₅₀ = 2.6 μM).

Product Specifications for CJ 033466

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CJ 033466

The following data is based on the product molecular weight 377.91.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.65 mL	13.23 mL	26.46 mL
5 mM	0.53 mL	2.65 mL	5.29 mL
10 mM	0.26 mL	1.32 mL	2.65 mL
50 mM	0.05 mL	0.26 mL	0.53 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Mikami 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-α]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroproki J.Pharmacol.Exp.Ther. 2008 PMID: 18198343
• Toga The 5-HT⁴ agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J.Pharmacol.Sci. 2007 PMID: 17928736

Product Documents for CJ 033466